Correspondence 0001493152-23-001585 from OKYO Pharma Ltd (OKYO) (CIK 0001849296) (OKYO)
OKYO Pharma Ltd (OKYO) (CIK 0001849296)
Date: Jan. 17, 2023 · CIK: 0001849296 · Accession: 0001493152-23-001585
AI Filing Summary & Sentiment
File numbers found in text: 333-268675
Letter
January 17, 2023
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
F Street, NE
Washington, D.C. 20549
Attn:
Tyler Howes
Re: OKYO Pharma LTD (the “Company”)
Registration Statement on Form F-1/A
File No. 333-268675
Acceleration Request
Requested Date: January 19, 2023
Requested Time: 5:00 p.m., Eastern Standard Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), ThinkEquity LLC, as representative of the several underwriters, hereby joins the Company in requesting that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form F-1/A (File No. 333-268675) (the “Registration Statement”) to become effective on Thursday, January 19, 2023, at 5:00 p.m., Eastern Standard Time, or as soon as practicable thereafter.
Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.
We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.
[Signature Page Follows]
Securities and Exchange Commission, p. 2
January 17, 2023
Very
truly yours,
ThinkEquity
LLC
Show Raw Text
CORRESP
1
filename1.htm
January
17, 2023
Via
EDGAR
Securities
and Exchange Commission
Division
of Corporation Finance
100
F Street, NE
Washington, D.C. 20549
Attn:
Tyler
Howes
Re:
OKYO
Pharma LTD (the “Company”)
Registration
Statement on Form F-1/A
File
No. 333-268675
Acceleration
Request
Requested
Date: January 19, 2023
Requested
Time: 5:00 p.m., Eastern Standard Time
Ladies
and Gentlemen:
In
accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), ThinkEquity LLC, as representative
of the several underwriters, hereby joins the Company in requesting that the Securities and Exchange Commission (the “Commission”)
take appropriate action to cause the Registration Statement on Form F-1/A (File No. 333-268675) (the “Registration Statement”)
to become effective on Thursday, January 19, 2023, at 5:00 p.m., Eastern Standard Time, or as soon as practicable thereafter.
Pursuant
to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus,
to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.
We
have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities
Exchange Act of 1934, as amended, to the extent applicable.
[Signature
Page Follows]
Securities
and Exchange Commission, p. 2
January
17, 2023
Very
truly yours,
ThinkEquity
LLC
By:
/s/
Priyanka Mahajan
Name:
Priyanka
Mahajan
Title:
Managing
Director, Investment Banking
cc:
Gary
Jacob, OKYO Pharma Ltd
Jeffrey
Fessler, Sheppard, Mullin, Richter & Hampton LLP
Anthony
Marsico, Dorsey & Whitney LLP